Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease

Jul 09, 2019

Overview : Trial Reference Manson JE, Cook NR, Lee IM, Christen W, VITAL Research Group. Vitamin D supplements and prevention of cancer and cardiovascular disease (VITAL). N Engl J Med. 2019 Jan 3;380(1):33-44. Abstract | Full Text   Expert Comment Ricardo Lopez Santi, ISCP Governor for Argentina... more

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia: The REDUCE-IT trial

Apr 01, 2019

Overview : Trial Reference Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22. Abstract | Full Text Expert Comment Maria Eliane Campos Magalhães and Andréa Araujo Brandão Background A long-standing association... more

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

Feb 28, 2019

Overview : Trial Reference Connolly SJ, Crowther M, Eikelboom JW, et al.; ANNEXA-4 Investigators. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019 Feb 7 [Epub ahead of print]. Abstract | Full Text   Expert... more

Intravenous Iron in Patients Undergoing Maintenance Hemodialysis: the PIVOTAL trial

Feb 14, 2019

Overview : Trial References Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Tomson CRV, Wheeler DC, Winearls CG, and Ford I, for the PIVOTAL Investigators and Committees. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.... more

Use of Aspirin to Reduce Risk of Initial Vascular Events in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE Trial)

Aug 27, 2018

Overview : Use of Aspirin to Reduce Risk of Initial Vascular Events in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE): A Randomised, Double-blind, Placebo-controlled Trial Trial Reference Gaziano JM, Brotons C, Coppolecchia R, et al. Use of Aspirin to Reduce Risk... more

A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest

Aug 27, 2018

Overview : Trial Reference Perkins GD, Ji C, Deakin CD, et al.; PARAMEDIC2 Collaborators. A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest. N Engl J Med. 2018 Jul 18. doi: 10.1056/NEJMoa1806842. [Epub ahead of print] Abstract | Full Text Expert Comment Pablo Avanzas, Consultant... more

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

Mar 22, 2018

Overview : Trial Reference White WB, Saag KG, Becker MA, et al; CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 12. doi: 10.1056/NEJMoa1710895. [Epub ahead of print] Abstract | Full Text   Expert Comment... more

6-Month Versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE): A Randomised, Open-label, Non-inferiority Trial

Mar 20, 2018

Overview : Trial Reference Hahn JY, Song YB, Oh JH, et al; SMART-DATE investigators. 6-Month Versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE): A Randomised, Open-label, Non-inferiority Trial. Lancet. 2018 Mar 9.... more

Anti-inflammatory Therapy with Canakinumab for Atherosclerotic Disease

Sep 06, 2017

Overview : Trial Reference Ridker PM, Everett BM, Thuren T et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Aug 27 [Epub ahead of print]. Abstract | Full Text   Expert Comment Pablo Avanzas, Consultant in Interventional Cardiology, Hospital... more

ODYSSEY Long Term Study

Oct 15, 2014

Overview : The Odyssey Long Term Study evaluated the safety and efficacy of alirocumab (mAb anti-PCSK9) in 2341 patients with heterozygous FH or at high risk for cardiovascular events who were receiving a maximally tolerated dose of statin but who had an... more

Page: